Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.
By B. Fisher, J. Dignam, J. Bryant, N. Wolmark. Journal of the National Cancer Institute, 2001
660 citations recorded by the source corpus.
Subfields: Cancer Research, Genetics, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/d36cb2a8c1335a15145544d3f338911d5b7fbb3f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- H. Burstein
- E. Winer
- A. Lipton
- B. Hillner
- S. Temin
- C. Hudis
- Holly Anderson
- T. Buchholz
Citations in the corpus
- American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. (2003, background): “tamoxifen use has been associated with more recurrences and deaths than 5 years of tamoxifen.(42) In addition, laboratory studies show that raloxifene may stimulate tamoxifen-dependent cells.”
- Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. (2014, background): “03); there was statistically significant greater recurrence in years zero to 5 years and not in 6 years.(12)”